



2nd EU HCV Summit “Securing sustainable funding for HCV elimination plans”

Date: 6th June 2018 11:30 to 18:00

**Venue: Steigenberger Wiltcher’s, Brussels, Belgium
Ballroom A**

Programme

<i>Timing</i>	<i>Agenda Item</i>	<i>Speaker</i>
11:30 – 12:00	Registration and welcoming coffee	
12:00 – 12:30	Welcome and introduction Chair: Prof. Angelos Hatzakis, Prof. Michael Manns	
	<p>Welcome to event and scene setting</p> <p>“MEP Friends of the Liver Group”</p> <p>“European Liver Patients’ Association”</p> <p>“EASL’s actions to achieve HCV Elimination in Europe”</p> <p>“European Civil Society Forum”</p>	<p>Prof. Michael Manns, Co-Chair, Hepatitis B&C Public Policy Association</p> <p>Prof. Angelos Hatzakis, Co-Chair, Hepatitis B&C Public Policy Association</p> <p>Dr. Cristian-Silviu Buşoi, Member of the European Parliament and Co-Chair of the Friends of the Liver MEP Group</p> <p>Dr. Tatjana Reic, President of the European Liver Patients’ Association, Chair of ACHIEVE Coalition</p> <p>Prof. Francesco Negro, Educational Councillor, European Association for the Study of Liver</p> <p>Eberhard Schatz, Coordinator, CORRELATION Network & European Civil Society Forum</p>
12:30 – 13:10	Session 1 : Burden of disease and pathways of elimination Chair: Prof. Georgios Papatheodoridis, Prof. Mojca Maticic	
	<p>“HCV Elimination in Europe: Burden Pathways and Cost”</p> <p>“The micro-elimination approach to eliminating hepatitis”</p> <p>“WHO-EURO: Progress Report”</p>	<p>Dr. Homie Razavi, Managing Director, The Centre for Disease Analysis Foundation</p> <p>Prof. Jeffrey Lazarus, Associate Professor, University of Barcelona, ISGlobal</p> <p>Dr. Antons Mozalevskis, Medical Officer, WHO Regional Office for Europe</p>
13:10 – 13:30	Questions & Answers	

13:30 – 14:00	Lunch break	
14:00 – 14:15	Keynote address Chair: Prof. Minerva-Melpomeni Malliori	
	<i>"Policy actions to secure long-term funding for hepatitis elimination"</i>	President George A. Papandreou , <i>President of the Socialist International, Former Prime Minister of Greece</i>
14:15 – 15:05	Session 2: The cost of HCV Elimination Chair: Prof. Francesco Negro, Prof. Sharon Hutchinson	
	<i>"Cost of HCV elimination: Direct medical cost, patients reported outcomes and productivity loss"</i>	Dr. Zobair Younossi , <i>Chairman, Department of Medicine, Inova Fairfax Medical Campus</i>
	<i>"Cost of screening"</i>	Prof. Sylvie Deufic-Burban , <i>French National Institute of Health and Medical Research (INSERM)</i>
	<i>"Price tag for bringing hepatitis B and C services under the umbrella of Universal Health Coverage"</i>	Dr. David Tordrup , <i>WHO Consultant, WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht University</i>
	<i>"Is hepatitis C elimination cost saving?"</i>	Prof. Jagpreet Chhatwal , <i>Assistant Professor, Harvard Medical School</i>
15:05 – 15:25	Questions & Answers	
15:25 – 15:45	Coffee Break	
15:45 – 16:20	Session 3: Innovative financing Chairs: Prof. Markus Peck-Radosavljevic, Prof. Dr. Nurdan Tözün	
	<i>"Innovative financing of HCV Elimination"</i>	Prof. Jagpreet Chhatwal , <i>Assistant Professor, Harvard Medical School</i>
	<i>"Financing solutions for hepatitis elimination in low and middle income countries"</i>	Dr. Homie Razavi , <i>Managing Director, The Centre for Disease Analysis Foundation</i>
16:20 – 16:40	Questions & Answers	
16:40 – 17:20	Session 4: Opportunities and challenges Chairs: Prof. Gamal Esmat, Prof. Dr. Charles Boucher	
	<i>"ACHIEVE-Association Collaborating on Hepatitis to Immunize and Eliminate the Viruses in Europe"</i>	Dr. Tatjana Reic , <i>President of the European Liver Patients Association, Chair of ACHIEVE Coalition</i>
	<i>"European Civil Society Forum"</i>	Eberhard Schatz , <i>Coordinator, CORRELATION network & European Civil Society Forum</i>
	<i>"Hepatitis C: Political leadership for elimination"</i>	Dr. Ricardo Baptista Leite , <i>Member of Portuguese Parliament</i>
17:20 – 17:40	Questions & Answers	
17:40 – 18:00	Wrap-up	
	<i>Next steps & invitation to Call to Action</i>	Prof. Angelos Hatzakis , <i>Co-Chair, Hepatitis B&C Public Policy Association</i> Prof. Jeffrey Lazarus , <i>Associate Professor, University of Barcelona, ISGlobal</i>



GILEAD

abbvie



MSD